Xtant Medical Holdings Inc（XTNT）の財務XTNTXtant Medical Holdings Inc

Xtant Medical Holdings Inc (XTNT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Orthobiologics, accounting for 74.7% of total sales, equivalent to $15.61M. Another important revenue stream is Spinal implant. Understanding this composition is critical for investors evaluating how XTNT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Xtant Medical Holdings Inc maintains a gross margin of 57.88%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -18.10%, while the net margin is -40.87%. These profitability ratios, combined with a Return on Equity (ROE) of -25.16%, provide a clear picture of how effectively XTNT converts its operational activities into shareholder value.

In the context of the broader market, XTNT competes directly with industry leaders such as HBIO and CVRX. With a market capitalization of $39.51M, it holds a leading position in the sector. When comparing efficiency, XTNT's gross margin of 57.88% stands against HBIO's 51.96% and CVRX's 87.39%. Such benchmarking helps identify whether Xtant Medical Holdings Inc is trading at a premium or discount relative to its financial performance.

Xtant Medical has shown fluctuating revenue, with Q2 2026 revenue at $23.03 million and a gross margin of 57.88%. However, it has raised its 2026 revenue guidance to between $101 million and $105 million, indicating growth potential.